Trial Profile
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Elagolix (Primary) ; Estradiol/norethisterone (Primary)
- Indications Menorrhagia; Uterine leiomyoma
- Focus Pharmacodynamics; Registrational
- Sponsors AbbVie
- 30 Oct 2023 Planned End Date changed from 2 Jul 2024 to 16 Jul 2024.
- 14 Feb 2023 Planned End Date changed from 24 Jan 2025 to 2 Jul 2024.
- 14 Feb 2023 Planned primary completion date changed from 18 Aug 2023 to 27 Nov 2023.